This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Micheau, O.
Right arrow Articles by Tschopp, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Micheau, O.
Right arrow Articles by Tschopp, J.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, August 2001, p. 5299-5305, Vol. 21, No. 16
0270-7306/01/$04.00+0   DOI: 10.1128/MCB.21.16.5299-5305.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

NF-kappa B Signals Induce the Expression of c-FLIP

Olivier Micheau,1 Susanne Lens,1 Olivier Gaide,1 Kostis Alevizopoulos,2 and Jürg Tschopp1,*

Institute of Biochemistry, University of Lausanne, BIL Biomedical Research Center,1 and Apotech Biochemicals, Biopôle,2 CH-1066 Epalinges, Switzerland

Received 1 February 2001/Returned for modification 16 March 2001/Accepted 24 May 2001


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Activation of the transcription factor NF-kappa B is a major effector of the inducible resistance to death receptor-mediated apoptosis. Previous evidence indicates that the combined transcriptional activation of TRAF-1, TRAF-2, IAP-1, and IAP-2 is required to suppress cell death by tumor necrosis factor (TNF). Here we show that NF-kappa B activation upregulates the caspase 8 inhibitor FLIP, resulting in increased resistance to Fas ligand (FasL) or TNF. Restoration of either the full-length 55-kDa long form of FLIP or an alternatively spliced short form of FLIP in NF-kappa B null cells inhibits TNF- and FasL-induced cell death efficiently, whereas the expression of IAP or TRAF family members only partially rescues cells from death. Resistance to either FasL- or TNF-induced apoptosis is overcome when cells are incubated in the presence of the protein synthesis inhibitor cycloheximide. This treatment leads to the rapid downregulation of FLIP but not to that of TRAF2. Our findings suggest that FLIP is an important mediator of NF-kappa B-controlled antiapoptotic signals.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Members of the tumor necrosis factor (TNF) receptor family and their corresponding ligands are critical regulators of apoptosis and various other cellular processes. Some of the receptors (Fas, TNF-R1, TRAIL-R1, TRAIL-R2, TRAMP/DR3, DR6, and EDA-R) contain a cytoplasmic region, called the death domain (DD), which is essential for cell death signaling (18, 22). Signals emanating from Fas and TNF-R1 have been intensively studied (14). Upon receptor activation, the DD of Fas undergoes direct homotypic interaction with a DD in the adapter protein FADD, while FADD recruitment is indirect (via TRADD) in the case of TNF-R1 (4). The death effector domain (DED) at the amino terminus of FADD then recruits pro-caspase 8 via homotypic interaction with its two DEDs. The high local concentration of caspase 8 zymogens facilitates self-processing and assembly of the mature enzyme. Activated caspase 8 initiates apoptosis by subsequent cleavage of downstream caspases (caspase-3, -6, and -7).

Death induced by death receptors is tightly regulated by genes that are activated by the transcription factor NF-kappa B (25). Modulation of the response in favor of NF-kappa B protects cells from apoptosis; failure to do so results in increased cell death. At least six NF-kappa B-responsive genes are involved in this survival amplification loop (26), i.e., those that encode IAP-1 and IAP-2, which block caspase activity (7); that which encodes the Bcl-2 family member A1 (25); and those that encode TRAF-1, TRAF-2 (1), and A20 (21), which are themselves implicated in the NF-kappa B signaling pathway. However, overexpression of all of these genes affords, at best, partial protection, in particular from death triggered by TNF (25). The only known potent inhibitor of death receptor signals is c-FLIP. Two c-FLIPs have been characterized (23, 24). The full-length 55-kDa-long form of FLIP (FLIPL) exhibits overall structural homology to caspase 8, containing two DEDs that interact with FADD and an inactive caspase-like domain. An alternatively spliced short form of FLIP (FLIPS) contains only the two DEDs and displays reduced antiapoptotic capacity.

We undertook a series of experiments to investigate whether c-FLIP is implicated in the antiapoptotic NF-kappa B response. Here we provide evidence that FLIP expression is upregulated upon the stimulation of several signaling pathways that are known to trigger activation of the transcription factor NF-kappa B. Moreover, we found that cells that were rendered highly sensitive to death ligand-induced apoptosis by blocking NF-kappa B activation could be rescued by expressing FLIP. FLIP may therefore play a key role in the NF-kappa B-mediated control of death signals.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Antibodies and materials. Rabbit anti-TRAF2 polyclonal antibody C20, rabbit anti-cIAP1 polyclonal antibody H-85, and mouse anti-TRAF1 monoclonal antibody H3 were purchased from Santa Cruz Biotechnology (Santa Cruz, Calif.). Rat anti-cFLIP monoclonal antibody Dave II was from Alexis, Lausen Switzerland, and anti-Phospho-Ikappa Ba antibody was from Biolab. Anti-tubulin and anti-Flag (M2) antibodies were from Sigma (St Louis, Mo.). Anti-myc tag antibody (9E10) and anti-hemagglutinin (anti-HA) antibody were purchased from Babco (Berkeley, Calif.). Anti-mouse CD40 antibody (hybridoma FGK45) was a gift from Ton Rolink (Basel, Switzerland). Human recombinant ligands (TRAIL, Fas ligand [FasL], and TNF) were obtained from Alexis. Lipopolysaccharide (LPS), phorbol myristate acetate (PMA), ionomycin, and granulocyte-macrophage colony-stimulating factor were from Sigma.

Cell culture. HeLa and HT1080 (human fibrosarcoma) cells, wild type (wt) and I-kappa B mutant (I-kappa Bmut), were cultured in Dulbecco's modified Eagle's medium (Gibco BRL Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum and penicillin and streptomycin (each at 50 µg/ml) and grown in 5% CO2 at 37°C. Mouse lymphoma EL4 and A20 cells and Jurkat cells were cultured as described above in RPMI 1640 medium. Dendritic cells were obtained from purified human CD34+ cells as described previously (2). NEMO-deficient cells were a kind gift of S. C. Sun (8).

Retrovirus production and cell transduction. The retroviral vector pBabe-Puro and generation of viruses have been described previously (17). Human Flag-tagged FLIPL, HA-tagged FLIPS, Flag-tagged TRAF1, Flag-tagged TRAF2, and myc-tagged c-IAP1 were subcloned, respectively, from pcDNA3 plasmids (10, 11) into pBabe-Puro. HT1080 wt or I-kappa Bmut cells (1.5 × 106) (10) were transduced for 16 h with viral supernatants containing Polybrene (8 µg/ml). Cells were washed once in phosphate-buffered saline, harvested, plated in complete medium containing puromycin (2.5 µg/ml), and incubated for 3 days before amplification and subsequent analysis of the multiclonal population.

Cell death and viability assays. Jurkat cells were harvested, washed with RPMI medium, and plated at a density of 10 × 106/ml prior to stimulation with PMA at 20 ng/ml and 1 mM ionomycin. HT1080 fibrosarcoma cells or transfectants derived therefrom (1.5 × 104 per well) were seeded in 96-well microtiter plates in the presence of the indicated reagents for 16 h, and viability was determined by the methylene blue colorimetric assay (16). For HeLa cells, viability was determined by the PMS-MTS method in accordance with the manufacturer's (Promega, Madison, Wis.) instructions. In some experiments, the number of apoptotic cells was determined by Hoechst staining. To quantitate viability and apoptosis in experiments involving EL4 and A20 cells, phosphatidylserine exposure on apoptotic cells was measured as described previously (13). Briefly, cells (2 × 105) were washed in ice-cold HEPES buffer (10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, pH 7.4) supplemented with glucose at 1 mg/ml and 0.5% bovine serum albumin. Fluorescein isothiocyanate-labeled annexin V (Nexins Research, Kattendijke, The Netherlands) was added to a final concentration of 2.5 µg/ml. Cells were incubated for 20 min at 4°C and washed twice with HEPES buffer. Before analysis on a FACScan, propidium iodide (PI) was added (final concentration, 5 µg/ml) to the samples to discriminate necrotic cells (annexin V- PI+) from apoptotic cells (annexin V+ PI- and annexin V+ PI+).

Western blotting. Cell lysates were prepared in NP-40 buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 10% glycerol, 0.2% NP-40) supplemented with a protease inhibitor cocktail stock solution (Roche Biochemicals, Basel, Switzerland). Cell debris was removed by centrifugation at 10,000 × g for 10 min, and the protein concentration was determined by the Bradford assay (Pierce, Rockford, Ill.). Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes by electroblotting, and nonspecific binding sites were blocked by incubation in PBS containing 0.5% Tween 20 and 5% (wt/vol) dry milk. Immunoblot analyses were performed with the indicated antibodies. Bound primary antibodies were visualized with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (IgG), goat anti-rat IgG, or goat anti-mouse IgG (Jackson Immunoresearch Laboratories, West Grove, Pa.) and ECL (Amersham, Freiburg, Germany).

RNase protection assay. HT1080 wt or I-kappa Bmut cells were treated with TNF for the times indicated in Results. Total RNA was isolated with the RNA INSTAPURE kit (Eurogentech, Seraing, Belgium) in accordance with the manufacturer's recommendations. The presence of transcripts of the indicated apoptosis-related genes, as well as the internal controls L32 and glyceraldehyde-3-phosphate dehydrogenase was analyzed by using the hApo3b, hApo5 Multi-Probe template sets (PharMingen, San Diego, Calif.). Probe synthesis, hybridization, and RNase treatment were performed with the RiboQuant Multi-Probe RNase Protection Assay System (PharMingen) in accordance with the manufacturer's recommendations. Finally, protected transcripts were resolved by electrophoresis on denaturing polyacrylamide gels (5%) and quantified on a PhosphorImager with the ImageQuant software (Molecular Dynamics, Sunnyvale, Calif.). To correct signals of protected transcripts of special interest for background intensity, the latter was determined for each individual lane in close proximity to the respective mRNA signal and subtracted from the value of the protected transcript.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The short-lived FLIP protein is induced in response to stimuli known to induce NF-kappa B activation. The murine B-cell line A20 is highly susceptible to Fas-mediated apoptosis but can be rescued by signaling through its surface B-cell receptor (6, 27). This effect has been attributed to the upregulation of Bcl-2 family members (6) and/or FLIP (27). The precise signaling pathways which result in the upregulation of the inhibitory proteins is, however, not known. As activation of the transcription factor NF-kappa B is frequently involved in the protection of cells from apoptosis, we considered the possibility that the gene for FLIP is also a target of the NF-kappa B transcription factor. Stimulation of the CD40 receptor is known to strongly activate NF-kappa B via recruitment of several TRAF proteins. Murine A20 B cells were therefore stimulated with agonistic antibodies to CD40 for 6 h before FasL addition. Whereas more than 80% of the cells were killed at a FasL concentration of 100 ng/ml, only 25% underwent apoptosis when cells had been prestimulated with anti-CD40 antibodies (Fig. 1A). Western blot analysis revealed that CD40-stimulated cells had a considerably increased concentration of FLIP, whereas caspase 8 levels remained unchanged (data not shown). Upon recruitment to death receptors, FLIPL is cleaved by caspase 8 between the large and small subunits in the caspase-like region, thereby inhibiting caspase 8 activity (11). In FasL-sensitive cells not prestimulated with TNF or CD40 and thus without increased FLIP levels, only processed FLIP (p43) was detectable after FasL addition, indicating that the entire cellular FLIP pool had been used up to form caspase 8-FLIP heterodimers, thus leaving some caspase 8 unprotected. As a consequence, caspase 8-caspase 8 homodimer formation was possible, resulting in caspase 8 autoactivation and cell death. By contrast, in CD40-prestimulated cells, a substantial amount of the increased concentration of precursor FLIP was still discernible after FasL treatment, indicating that the FLIP concentration was still sufficiently high to block the full processing of all of the caspase 8 molecules that were recruited to the Fas signaling complex (DISC).


View larger version (37K):
[in this window]
[in a new window]
  		FIG. 1.   Anti-CD40, TNF, or LPS stimulation upregulates FLIP and partly protects from FasL-mediated apoptosis. (A) A20 lymphoma cells were pretreated for 24 h with anti-CD40 at 10 µg/ml and treated with recombinant Flag-tagged FasL (33 ng/ml) in the presence of cross-linking anti-Flag antibodies at 1 µg/ml for 8 h. Apoptosis was quantified by annexin V staining, and FLIP protein content was determined by Western blotting with an anti-FLIP antibody. (B) Human dendritic cells were either nontreated (left lane) or incubated with TNF (40 ng/ml) or LPS (10 µg/ml) for 24 h and analyzed by immunoblot assay for the expression of FLIP and TRAF1.

We next investigated the capacity of two other stimuli which induce NF-kappa B activation to upregulate FLIP expression. Immature human monocyte-derived dendritic cells are resistant to FasL (3, 19), possibly due to the high FLIP levels already present even in nonmature cells (Fig. 1B). Dendritic cell maturation can be achieved by treating cells with agents that trigger NF-kappa B activation, such as LPS or TNF (5), and this is reflected by the strong increase in the NF-kappa B-responsive protein TRAF1 (Fig. 1B). We observed that not only the expression of FLIPL but also that of FLIPS was strongly increased in response to a 2-day treatment with LPS and TNF (Fig. 1B).

Resistant dendritic cells can be rendered sensitive to FasL by the protein synthesis inhibitor cycloheximide (CHX) (28). This was correlated with the disappearance of FLIPL. We confirmed these observation (data not shown). To explore whether FLIP was also short-lived in other cells, the murine T-cell lymphoma cell line EL-4 and the human adenocarcinoma line HeLa, which are both reasonably resistant to apoptosis when treated with FasL at 100 ng/ml, were incubated with increasing doses of CHX (Fig. 2A and B). In both cell lines, incubation with CHX at 0.5 µg/ml for 16 h sufficed to cause the disappearance of detectable levels of FLIPL protein, whereas levels of alpha -tubulin or of the antiapoptotic gene TRAF-2 remained unchanged. The same sensitivity to CHX was also observed for FLIPS, which, in contrast to EL-4 cells, is expressed in HeLa cells. As a consequence of the addition of the protein synthesis inhibitor, EL-4 and HeLa cells became sensitive to FasL (Fig. 2A and B) and underwent apoptosis at CHX concentrations that were identical to those required for FLIP downregulation. Thus, FLIP appears to be short-lived in several cell lines, requiring continuous biosynthesis to ensure levels that are required for protection against apoptosis.


View larger version (45K):
[in this window]
[in a new window]
  		FIG. 2.   FLIP downregulation by CHX enhances FasL-induced apoptosis in EL4 and HeLa cells. (A) EL-4 cells were treated with increasing concentrations of CHX in the presence or absence of cross-linked (+M2) FasL at 100 ng/ml for 16 h. Cell viability was subsequently determined by fluorescence-activated cell sorting using annexin V staining. FLIP and tubulin protein contents were determined by immunoblot assay. (B) HeLa cells were treated and analyzed as described above, except that viability was determined by the PMS-MTS method. In addition to FLIP and tubulin contents, TRAF2 protein content was analyzed by immunoblot assay. OD490, optical density at 490 nm.

The gene for FLIP is an NF-kappa B-responsive gene. The above-described experiments suggested that FLIP is upregulated in response to signals that lead to NF-kappa B activation. To corroborate this notion, we took advantage of the HT1080 fibrosarcoma cell line, which expresses a modified form of the NF-kappa B inhibitor I-kappa Balpha that cannot be degraded due to mutated phosphorylation sites (10, 26). In this cell line (I-kappa Bmut), translocation of NF-kappa B into the nucleus is highly impaired, and thus, synthesis of NF-kappa B-responsive genes does not occur (10, 26). As a result, the mutant cell line is highly susceptible to death signals such as TNF and FasL (10, 26). Both wt and mutant HT1080 cells were treated with small doses of TNF to stimulate NF-kappa B activation, which, as expected, led to a high level of expression of NF-kappa B-responsive TRAF-1 in the wt cells but not in the in the I-kappa Bmut HT1080 cells (Fig. 3A). At the TNF concentration used (50 ng/ml), expression of TRAF-1 was detectable at 4 h and reached a maximum between 10 and 24 h, at a time where no cell death was observed in the I-kappa Bmut cells, and thus the absence of TRAF-1 expression cannot be attributed to cell death (wt HT1080 cells). The low concentration of FLIP which is already present in HT1080 cells before stimulation was increased in wt but not mutant HT1080 cells, indicating that activation of NF-kappa B is required for FLIP induction (Fig. 3A). Interestingly, the kinetics of induction of the two forms of FLIP differed. While FLIPS was already detectable 4 h after the addition of TNF, induction of FLIPL was slower and peaked between 10 and 24 h, when the levels of FLIPS had already decreased. TNF also induced a considerable induction of FLIP mRNA levels (Fig. 3B), demonstrating that the increase in FLIP protein was, at least in part, due to increased NF-kappa B-mediated transcription of the gene for FLIP. While the well-described increase in the TRAF-1 and c-IAP-1 messages could be confirmed in our experimental setting, no substantial increase, however, in TRAF-2 and c-IAP-2 was observed. When the resistance to FasL of the HT1080 cells was subsequently analyzed, wt but not I-kappa Bmut cells showed increased resistance to FasL upon TNF pretreatment (Fig. 4), correlating with the increased FLIP levels. Taken together, these results indicate that FLIP, similar to the antiapoptotic TRAF and IAP family members (26), is positively regulated by NF-kappa B following TNF addition.


View larger version (47K):
[in this window]
[in a new window]
  		FIG. 3.   NFkappa -B activation leads to FLIP protein and mRNA upregulation. (A) The HT1080 fibrosarcoma cell line (wt or I-kappa Bmut), stably transfected with a myc-tagged, mutated, nondegradable version of I-kappa Balpha , were treated for the indicated periods of time with TNF at 50 ng/ml and analyzed for FLIPL, FLIPS, and TRAF1 expression by immunoblot assay. (B) RNase protection assay analysis of mRNA levels of various apoptosis-related genes in wt or I-kappa Bmut HT1080 cells after treatment with TNF as described above, using different hApo multiprobe template sets. L32 and glyceraldehyde-3-phosphate dehydrogenase (GADPH) were included in each template set as internal controls.


View larger version (68K):
[in this window]
[in a new window]
  		FIG. 4.   NF-kappa B-mediated upregulation of FLIP protects from Fas-induced apoptosis. HT1080 wt or I-kappa Bmut cells were pretreated for 2 h with TNF at 50 ng/ml, washed with fresh medium, and subsequently incubated in the presence of cross-linked FasL at 100 ng/ml for 8 h. Apoptosis was quantified by Hoechst staining. FLIP and TRAF1 protein contents were analyzed by immunoblot assay. Compared to Fig. 2, a longer exposure time was chosen to reveal the cleavage of FLIPL into its p43 fragment upon treatment with FasL. The values beside the lower left-hand images are molecular sizes in kilodaltons.

To demonstrate that the NF-kappa B dependence of FLIP expression is a more general phenomenon and not restricted to a single cell type, we investigated FLIP expression in the Jurkat T-cell line. Assembly of the IKK signalosome and successful signal transmission are dependent on NEMO/IKKgamma , which acts as a scaffolding protein (15). We therefore compared FLIP induction by two known stimuli of NF-kappa B activation in Jurkat cells, i.e., PMA-ionomycin and TNF, in wt Jurkat cells and in Jurkat cells that are genetically deficient in NEMO (8). Upon addition of PMA-ionomycin, levels of FLIPL, which was barely detectable in unstimulated cells, increased 10 min after stimulation and peaked after 2 to 4 h (Fig. 5A). In contrast to HT1080 cells, FLIPS was induced after FLIPL in Jurkat cells. This sequence of events was previously observed in primary T cells (9), indicating that the control of expression of the two FLIP splice variants is cell type specific. When NF-kappa B was activated with TNF, FLIPL increased with similar kinetics (Fig. 5B). The absolute increase in FLIPL was smaller than in cells stimulated with PMA-ionomycin, which adequately reflects the fact that the latter stimulus is more potent. No or little FLIP protein induction was observed in NEMO-deficient cells not exposed to the stimulus (Fig. 5A and B). The absence of NF-kappa B activity in NEMO-deficient cells rendered Jurkat cells sensitive to TNF, while the parental cell line was completely resistant to TNF-mediated apoptosis (Fig. 5C).


View larger version (27K):
[in this window]
[in a new window]
  		FIG. 5.   NFkappa -B activation leads to FLIP upregulation in Jurkat T cells. (A) Both wt and NEMO (N.)-deficient (def.) Jurkat cells were stimulated for the indicated periods of time with PMA and ionomycin (Iono) (or phosphate-buffered saline [control]) and analyzed for FLIPL, FLIPS, and phosphorylated Ikappa B expression by immunoblot assay. (B) Cells were stimulated with TNF at 100 ng/ml, and FLIPL expression was monitored as in panel A. Expression of NEMO is demonstrated on the right. (C) Cell death induced by TNF in wt and NEMO-deficient cells, respectively.

FLIP protects NF-kappa B-incompetent cells against death receptor-induced apoptosis. Previous results have suggested that the protective effect of NF-kappa B stimulation against death receptor (TNF)-induced apoptosis can be mimicked by simultaneously overexpressing the NF-kappa B-induced proteins TRAF-1, TRAF-2, c-IAP-1, and c-IAP-2 in I-kappa Bmut HT1080 cells, leading to a blockade of caspase 8 activation (26). All of these proteins, however, were, at best, partially protective when overexpressed individually (26). Given that FLIP appears to be the most potent inhibitor of death receptor signaling pathways and that FLIP is induced by NF-kappa B (see above), we considered the possibility that FLIP plays an even more important role than the TRAF and IAP proteins in the NF-kappa B antiapoptotic response. If this is so, overexpression of FLIP alone in I-kappa Bmut cells should have a strong protective effect against death receptor signals. In order to avoid the selection of apoptosis-resistant clones that frequently occurs when cells are cultured in drug-containing medium for a longer period of time, we chose to retrovirus infect cells and to analyze whole cell populations without further cloning efforts. FLIPL was highly expressed in several of the cell populations analyzed, and one example is shown in Fig. 6A. In contrast, FLIPS expression was always low, for reasons which are not understood. However, the low expression levels of FLIPS sufficed to protect the I-kappa Bmut cells from the apoptotic effect of TNF (Fig. 6B) while cell death still occurred at high concentrations of FasL and TRAIL. Cells expressing high levels of FLIPL were completely protected not only from TNF-induced cell death but also from FasL- and TRAIL-induced cell death, in agreement with previous results (11). We can exclude the possibility that this protection was due to the reactivation of the NF-kappa B response in I-kappa Bmut cells, as levels of I-kappa Bmut remained unchanged after viral infection (data not shown). Exogenous FLIP is also short-lived, and treatment of the infected cell population with CHX led to a decrease in FLIP expression after 4 h (data not shown) and to increased sensitivity to TNF in mock-infected and FLIPS-infected cells (Fig. 6C). By contrast, the amount of FLIPL remaining during the CHX treatment (FLIPL is expressed at much higher levels than FLIPS; Fig. 6A) was still enough to afford complete protection from TNF-mediated cell death.


View larger version (26K):
[in this window]
[in a new window]
  		FIG. 6.   FLIP overexpression protects from TNF-, FasL-, and TRAIL-induced cell death. (A) HA-tagged FLIPS, Flag-tagged FLIPL, and empty vectors were introduced into HT1080 wt or I-kappa Bmut cells by retrovirus infection. Cells were selected in puromycin for 3 days before analysis of protein content and function. FLIP expression was determined by immunoblot assay using an anti-FLIP antibody, anti-HA antibody, or anti-Flag antibody. The values on the right are molecular sizes in kilodaltons. (B) Infected pools of cells were treated with increasing concentrations of TNF, FasL, and TRAIL (control) in the presence of cross-linking antibody at 1 µg/ml (with the exception of TNF). Cell viability was determined 16 h after treatment. (C) Cell viability of the indicated cells pretreated or not pretreated with CHX (20 µg/ml for 1 h) after incubation (16 h) with increasing concentrations of TNF.

To confirm the previous findings by Baldwin's group (26) in the context of our experimental setting, we infected cells with viruses containing the genes for TRAF1, TRAF-2, and cIAP1 (Fig. 7). Despite reasonable expression levels of all of these proteins, they were incapable of fully protecting I-kappa Bmut cells against TNF-mediated apoptosis, in agreement with the published results.


View larger version (38K):
[in this window]
[in a new window]
  		FIG. 7.   TRAF1, TRAF2, or cIAP1 overexpression fails to protect HT1080 cells from TNF-, FasL-, and TRAIL-induced cell death. (A) pBape-Flag-tagged TRAF1 and TRAF-2 vectors were introduced by virus infection into HT1080 wt or I-kappa Bmut cells. TRAF1 and TRAF2 expression was determined by Western blot assay using anti-TRAF1, anti-Flag, or anti-TRAF2 antibodies. The sensitivity to TNF-mediated cell death of the cell pools obtained was determined essentially as described in the legend to Fig 5. (B) HT1080 wt or I-kappa Bmut cells were infected with either pBape-myc-tagged cIAP1 or empty vector. Cellular pools were analyzed for resistance to TNF as described above. The values beside the blots are molecular sizes in kilodaltons.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

In this report, we provide evidence that FLIP is one of several antiapoptotic genes that are under the control of the NF-kappa B transcription factor. It appears, however, that FLIP is more efficient than TRAF1, TRAF-2, cIAP-1, and c-IAP-2, which have been previously proposed to be responsible for the inhibition of death receptor-induced cell death (26). When expressed at equal levels, FLIPL was found to be by far the most potent inhibitor, and thus, FLIP may have a dominant role in the observed NF-kappa B-mediated resistance to death ligand-induced apoptosis. c-IAPs may be more important in mitochondrion-induced cell death, as they interact with caspase-9 and caspase-3 but not with caspase 8 (20). Moreover, the overexpression of TRAF1, TRAF-2, cIAP-1, and c-IAP-2 may result in their increased recruitment to signaling complexes, possibly resulting in an augmented NF-kappa B response. This, in turn, would upregulate FLIP levels and thus indirectly lead to the observed antiapoptotic response of the TRAF1, TRAF-2, cIAP-1, and c-IAP-2 proteins.

We observed that FLIPS and FLIPL are under the control of NF-kappa B, but interestingly, induction followed different kinetics. In HT1080 cells, FLIPS responded considerably more rapidly to TNF while FLIPS levels dropped at a time when FLIPL protein levels increased. During T-cell activation, the inverse order was observed (9). The reasons for this cell type-specific regulation are unknown.

We have previously shown that FLIPL, but not FLIPS, binds to TRAF2 and RIP, resulting in strong NF-kappa B activation upon stimulation of death receptor signaling pathways (12). Thus, it is conceivable that FLIP levels that are barely sufficient for protection against death receptors are augmented by an autoamplification loop. In fact, only small variations in FLIP protein levels may decide whether a cell is resistant or sensitive to death mediated by Fas or TNF. It appears that the recruitment of caspase 8-FLIP heterodimers is highly favored over the recruitment of caspase 8-caspase 8 homodimers, and thus, FLIP levels have to exceed caspase 8 levels to be protective. As caspase 8 levels are quite stable, with no or little variation in the presence of various stimuli, only a small increase in FLIP levels may decide whether a cell will respond by dying or living. It is therefore not surprising that FLIP levels are highly controlled. FLIP is an unstable protein and is rapidly degraded when neosynthesis is inhibited (conditions occurring during cell death). Preliminary results indicate that FLIP is ubiquitin modified under certain conditions, which may explain its short half-life. The ring finger domain of IAPs has been found to have ubiquitin E3 ligase activity, resulting in the transfer of ubiquitin to IAP and thus in its own degradation (29). Interestingly, the FLIP-binding protein TRAF2 also contains a ring finger domain, raising the possibility that the limited stability of FLIP is caused by its binding partner. We are currently testing this hypothesis.


    FOOTNOTES

* Corresponding author. Mailing address: Institute of Biochemistry, University of Lausanne, Ch. des Boveresses 155, CH-1066 Epalinges, Switzerland. Phone: 41 21 692 5738. Fax: 41 21 692 5705. E-mail: jurg.tschopp{at}ib.unil.ch.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Arch, R. H., R. W. Gedrich, and C. B. Thompson. 1998. Tumor necrosis factor receptor-associated factors (TRAFs)---a family of adapter proteins that regulates life and death. Genes Dev. 12:2821-2830[Free Full Text].
2. Arrighi, J. F., C. Hauser, B. Chapuis, R. H. Zubler, and V. Kindler. 1999. Long-term culture of human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34(-) CD14(-) and a CD34(-) CD14(+) dendritic cell precursor. Blood 93:2244-2252[Abstract/Free Full Text].
3. Ashany, D., A. Savir, N. Bhardwaj, and K. B. Elkon. 1999. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J. Immunol. 163:5303-5311[Abstract/Free Full Text].
4. Ashkenazi, A., and V. M. Dixit. 1998. Death receptors: signaling and modulation. Science 281:1305-1308[Abstract/Free Full Text].
5. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252[CrossRef][Medline].
6. Bras, A., A. C. Martinez, and E. Baixeras. 1997. B cell receptor cross-linking prevents Fas-induced cell death by inactivating the IL-1 beta-converting enzyme protease and regulating Bcl-2/Bcl-x expression. J. Immunol. 159:3168-3177[Abstract].
7. Deveraux, Q. L., N. Roy, H. R. Stennicke, T. Van Arsdale, Q. Zhou, S. M. Srinivasula, E. S. Alnemri, G. S. Salvesen, and J. C. Reed. 1998. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17:2215-2223[CrossRef][Medline].
8. Harhaj, E. W., L. Good, G. Xiao, M. Uhlik, M. E. Cvijic, I. Rivera-Walsh, and S. C. Sun. 2000. Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein. Oncogene 19:1448-1456[CrossRef][Medline].
9. Holler, N., R. Zaru, O. Micheau, M. Thome, A. Attinger, S. Valitutti, J. L. Bodmer, P. Schneider, B. Seed, and J. Tschopp. 2000. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1:489-502[CrossRef][Medline].
10. Irmler, M., V. Steiner, C. Ruegg, H. Wajant, and J. Tschopp. 2000. Caspase-induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-mediated apoptosis. FEBS Lett. 468:129-133[CrossRef][Medline].
11. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J. L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. E. French, and J. Tschopp. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195[CrossRef][Medline].
12. Kataoka, T., R. C. Budd, N. Holler, M. Thome, F. Martinon, M. Irmler, K. Burns, M. Hahne, N. Kennedy, M. Kovacsovics, and J. Tschopp. 2000. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and erk signaling pathways. Curr. Biol. 10:640-648[CrossRef][Medline].
13. Koopman, G., C. P. Reutelingsperger, G. A. Kuijten, R. M. Keehnen, S. T. Pals, and M. H. van Oers. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415-1420[Abstract/Free Full Text].
14. Krammer, P. H. 2000. CD95's deadly mission in the immune system. Nature 407:789-795[CrossRef][Medline].
15. Li, N., and M. Karin. 2000. Signaling pathways leading to nuclear factor-kappa B activation. Methods Enzymol. 319:273-279[Medline].
16. Micheau, O., E. Solary, A. Hammann, and M. T. Dimanche-Boitrel. 1999. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 274:7987-7992[Abstract/Free Full Text].
17. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596[Abstract/Free Full Text].
18. Nagata, S. 1997. Apoptosis by death factor. Cell 88:355-365[CrossRef][Medline].
19. Rescigno, M., V. Piguet, B. Valzasina, S. Lens, R. Zubler, L. French, V. Kindler, J. Tschopp, and P. Ricciardi-Castagnoli. 2000. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction. A new role for fas ligand in inflammatory responses. J. Exp. Med. 192:1661-1668[Abstract/Free Full Text].
20. Roy, N., Q. L. Deveraux, R. Takahashi, G. S. Salvesen, and J. C. Reed. 1997. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:6914-6925[CrossRef][Medline].
21. Sarma, V., Z. Lin, L. Clark, B. M. Rust, M. Tewari, R. J. Noelle, and V. M. Dixit. 1995. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J. Biol. Chem. 270:12343-12346[Abstract/Free Full Text].
22. Schulze-Osthoff, K., D. Ferrari, M. Los, S. Wesselborg, and M. E. Peter. 1998. Apoptosis signaling by death receptors. Eur. J. Biochem. 254:439-459[Medline].
23. Tschopp, J., M. Irmler, and M. Thome. 1998. Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol. 10:552-558[CrossRef][Medline].
24. Wallach, D. 1997. Apoptosis: placing death under control. Nature 388:123[CrossRef][Medline].
25. Wang, C.-Y., D. C. Guttridge, M. W. Mayo, and A. S. Baldwin, Jr. 1999. NF-kappa B induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 19:5923-5929[Abstract/Free Full Text].
26. Wang, C.-Y., M. W. Mayo, R. G. Korneluk, D. V. Goeddel, and A. S. Baldwin, Jr. 1998. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680-1683[Abstract/Free Full Text].
27. Wang, J., A. A. Lobito, F. Shen, F. Hornung, A. Winoto, and M. J. Lenardo. 2000. Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur. J. Immunol. 30:155-163[CrossRef][Medline].
28. Willems, F., Z. Amraoui, N. Vanderheyde, V. Verhasselt, E. Aksoy, C. Scaffidi, M. E. Peter, P. H. Krammer, and M. Goldman. 2000. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood 95:3478-3482[Abstract/Free Full Text].
29. Yang, Y., S. Fang, J. P. Jensen, A. M. Weissman, and J. D. Ashwell. 2000. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288:874-877[Abstract/Free Full Text].

Molecular and Cellular Biology, August 2001, p. 5299-5305, Vol. 21, No. 16
0270-7306/01/$04.00+0   DOI: 10.1128/MCB.21.16.5299-5305.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hailfinger, S., Lenz, G., Ngo, V., Posvitz-Fejfar, A., Rebeaud, F., Guzzardi, M., Penas, E.-M. M., Dierlamm, J., Chan, W. C., Staudt, L. M., Thome, M. (2009). Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA 106: 19946-19951 [Abstract] [Full Text]  
  • Cheung, H. H., Mahoney, D. J., LaCasse, E. C., Korneluk, R. G. (2009). Down-regulation of c-FLIP Enhances Death of Cancer Cells by Smac Mimetic Compound. Cancer Res. 69: 7729-7738 [Abstract] [Full Text]  
  • Giros, A., Grzybowski, M., Sohn, V. R., Pons, E., Fernandez-Morales, J., Xicola, R. M., Sethi, P., Grzybowski, J., Goel, A., Boland, C. R., Gassull, M. A., Llor, X. (2009). Regulation of Colorectal Cancer Cell Apoptosis by the n-3 Polyunsaturated Fatty Acids Docosahexaenoic and Eicosapentaenoic. Cancer Prevention Research 2: 732-742 [Abstract] [Full Text]  
  • Shi, B., Tran, T., Sobkoviak, R., Pope, R. M. (2009). Activation-induced Degradation of FLIPL Is Mediated via the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway in Macrophages. J. Biol. Chem. 284: 14513-14523 [Abstract] [Full Text]  
  • Clippinger, A. J., Gearhart, T. L., Bouchard, M. J. (2009). Hepatitis B Virus X Protein Modulates Apoptosis in Primary Rat Hepatocytes by Regulating both NF-{kappa}B and the Mitochondrial Permeability Transition Pore. J. Virol. 83: 4718-4731 [Abstract] [Full Text]  
  • Kurada, B. R. V. V. S. N., Li, L. C., Mulherkar, N., Subramanian, M., Prasad, K. V., Prabhakar, B. S. (2009). MADD, a Splice Variant of IG20, Is Indispensable for MAPK Activation and Protection against Apoptosis upon Tumor Necrosis Factor-{alpha} Treatment. J. Biol. Chem. 284: 13533-13541 [Abstract] [Full Text]  
  • Klemke, C.-D., Brenner, D., Weiss, E.-M., Schmidt, M., Leverkus, M., Gulow, K., Krammer, P. H. (2009). Lack of T-Cell Receptor-Induced Signaling Is Crucial for CD95 Ligand Up-regulation and Protects Cutaneous T-Cell Lymphoma Cells from Activation-Induced Cell Death. Cancer Res. 69: 4175-4183 [Abstract] [Full Text]  
  • Kadohara, K., Nagumo, M., Asami, S., Tsukumo, Y., Sugimoto, H., Igarashi, M., Nagai, K., Kataoka, T. (2009). Caspase-8 Mediates Mitochondrial Release of Pro-apoptotic Proteins in a Manner Independent of Its Proteolytic Activity in Apoptosis Induced by the Protein Synthesis Inhibitor Acetoxycycloheximide in Human Leukemia Jurkat Cells. J. Biol. Chem. 284: 5478-5487 [Abstract] [Full Text]  
  • Haimerl, F., Erhardt, A., Sass, G., Tiegs, G. (2009). Down-regulation of the De-ubiquitinating Enzyme Ubiquitin-specific Protease 2 Contributes to Tumor Necrosis Factor-{alpha}-induced Hepatocyte Survival. J. Biol. Chem. 284: 495-504 [Abstract] [Full Text]  
  • Caprioli, F, Stolfi, C, Caruso, R, Fina, D, Sica, G, Biancone, L, Pallone, F, Monteleone, G (2008). Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Gut 57: 1674-1680 [Abstract] [Full Text]  
  • Ch'en, I. L., Beisner, D. R., Degterev, A., Lynch, C., Yuan, J., Hoffmann, A., Hedrick, S. M. (2008). Antigen-mediated T cell expansion regulated by parallel pathways of death. Proc. Natl. Acad. Sci. USA 105: 17463-17468 [Abstract] [Full Text]  
  • Kavurma, M. M., Tan, N. Y., Bennett, M. R. (2008). Death Receptors and Their Ligands in Atherosclerosis. Arterioscler. Thromb. Vasc. Bio. 28: 1694-1702 [Abstract] [Full Text]  
  • Omori, E., Morioka, S., Matsumoto, K., Ninomiya-Tsuji, J. (2008). TAK1 Regulates Reactive Oxygen Species and Cell Death in Keratinocytes, Which Is Essential for Skin Integrity. J. Biol. Chem. 283: 26161-26168 [Abstract] [Full Text]  
  • Varfolomeev, E., Goncharov, T., Fedorova, A. V., Dynek, J. N., Zobel, K., Deshayes, K., Fairbrother, W. J., Vucic, D. (2008). c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor {alpha} (TNF{alpha})-induced NF-{kappa}B Activation. J. Biol. Chem. 283: 24295-24299 [Abstract] [Full Text]  
  • Mahoney, D. J., Cheung, H. H., Mrad, R. L., Plenchette, S., Simard, C., Enwere, E., Arora, V., Mak, T. W., Lacasse, E. C., Waring, J., Korneluk, R. G. (2008). Both cIAP1 and cIAP2 regulate TNF{alpha}-mediated NF-{kappa}B activation. Proc. Natl. Acad. Sci. USA 105: 11778-11783 [Abstract] [Full Text]  
  • Tun-Kyi, A., Qin, J. -Z., Oberholzer, P. A., Navarini, A. A., Hassel, J. C., Dummer, R., Dobbeling, U. (2008). Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Ann Oncol 19: 1488-1494 [Abstract] [Full Text]  
  • Ueffing, N., Schuster, M., Keil, E., Schulze-Osthoff, K., Schmitz, I. (2008). Up-regulation of c-FLIPshort by NFAT contributes to apoptosis resistance of short-term activated T cells. Blood 112: 690-698 [Abstract] [Full Text]  
  • Chan, G., Bivins-Smith, E. R., Smith, M. S., Yurochko, A. D. (2008). Transcriptome Analysis of NF-{kappa}B- and Phosphatidylinositol 3-Kinase-Regulated Genes in Human Cytomegalovirus-Infected Monocytes. J. Virol. 82: 1040-1046 [Abstract] [Full Text]  
  • Prabhakar, B. S., Mulherkar, N., Prasad, K. V. (2008). Role of IG20 Splice Variants in TRAIL Resistance. Clin. Cancer Res. 14: 347-351 [Abstract] [Full Text]  
  • Mandron, M., Martin, H., Bonjean, B., Lule, J., Tartour, E., Davrinche, C. (2008). Dendritic cell-induced apoptosis of human cytomegalovirus-infected fibroblasts promotes cross-presentation of pp65 to CD8+ T cells. J. Gen. Virol. 89: 78-86 [Abstract] [Full Text]  
  • Kanayama, A., Miyamoto, Y. (2007). Apoptosis triggered by phagocytosis-related oxidative stress through FLIPS down-regulation and JNK activation. J. Leukoc. Biol. 82: 1344-1352 [Abstract] [Full Text]  
  • Huang, X., Masselli, A., Frisch, S. M., Hunton, I. C., Jiang, Y., Wang, J. Y. J. (2007). Blockade of Tumor Necrosis Factor-induced Bid Cleavage by Caspase-resistant Rb. J. Biol. Chem. 282: 29401-29413 [Abstract] [Full Text]  
  • Zhang, X., Zhang, L., Yang, H., Huang, X., Otu, H., Libermann, T. A., DeWolf, W. C., Khosravi-Far, R., Olumi, A. F. (2007). c-Fos as a Proapoptotic Agent in TRAIL-Induced Apoptosis in Prostate Cancer Cells. Cancer Res. 67: 9425-9434 [Abstract] [Full Text]  
  • Rosato, R. R., Almenara, J. A., Coe, S., Grant, S. (2007). The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation. Cancer Res. 67: 9490-9500 [Abstract] [Full Text]  
  • Pattacini, L., Casali, B., Boiardi, L., Pipitone, N., Albertazzi, L., Salvarani, C. (2007). Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF-{kappa}B pathway. Rheumatology (Oxford) 46: 1252-1257 [Abstract] [Full Text]  
  • Rae, C., Langa, S., Tucker, S. J., MacEwan, D. J. (2007). Elevated NF-{kappa}B responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proc. Natl. Acad. Sci. USA 104: 12790-12795 [Abstract] [Full Text]  
  • Song, J. H., Tse, M. C.L., Bellail, A., Phuphanich, S., Khuri, F., Kneteman, N. M., Hao, C. (2007). Lipid Rafts and Nonrafts Mediate Tumor Necrosis Factor Related Apoptosis-Inducing Ligand Induced Apoptotic and Nonapoptotic Signals in Non Small Cell Lung Carcinoma Cells. Cancer Res. 67: 6946-6955 [Abstract] [Full Text]  
  • Wullaert, A., van Loo, G., Heyninck, K., Beyaert, R. (2007). Hepatic Tumor Necrosis Factor Signaling and Nuclear Factor-{kappa}B: Effects on Liver Homeostasis and Beyond. Endocr. Rev. 28: 365-386 [Abstract] [Full Text]  
  • Kim, S., Millet, I., Kim, H. S., Kim, J. Y., Han, M. S., Lee, M.-K., Kim, K.-W., Sherwin, R. S., Karin, M., Lee, M.-S. (2007). NF-{kappa}B prevents beta cell death and autoimmune diabetes in NOD mice. Proc. Natl. Acad. Sci. USA 104: 1913-1918 [Abstract] [Full Text]  
  • Krysov, S. V., Rowley, T. F., Al-Shamkhani, A. (2007). Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells. Molecular Cancer Therapeutics 6: 703-711 [Abstract] [Full Text]  
  • Testa, U., Riccioni, R. (2007). Deregulation of apoptosis in acute myeloid leukemia. haematol 92: 81-94 [Abstract] [Full Text]  
  • Jiang, Z., Clemens, P. R. (2006). Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells. FASEB J. 20: 2570-2572 [Abstract] [Full Text]  
  • Jin, Z., El-Deiry, W. S. (2006). Distinct Signaling Pathways in TRAIL- versus Tumor Necrosis Factor-Induced Apoptosis. Mol. Cell. Biol. 26: 8136-8148 [Abstract] [Full Text]  
  • Loeuillet, C., Martinon, F., Perez, C., Munoz, M., Thome, M., Meylan, P. R. (2006). Mycobacterium tuberculosis Subverts Innate Immunity to Evade Specific Effectors. J. Immunol. 177: 6245-6255 [Abstract] [Full Text]  
  • Gao, H., Xiao, J., Sun, Q., Lin, H., Bai, Y., Yang, L., Yang, B., Wang, H., Wang, Z. (2006). A Single Decoy Oligodeoxynucleotides Targeting Multiple Oncoproteins Produces Strong Anticancer Effects. Mol. Pharmacol. 70: 1621-1629 [Abstract] [Full Text]  
  • Merino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., Micheau, O. (2006). Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2.. Mol. Cell. Biol. 26: 7046-7055 [Abstract] [Full Text]  
  • Marciniak, S. J., Ron, D. (2006). Endoplasmic reticulum stress signaling in disease.. Physiol. Rev. 86: 1133-1149 [Abstract] [Full Text]  
  • Braeuer, S. J., Buneker, C., Mohr, A., Zwacka, R. M. (2006). Constitutively Activated Nuclear Factor-{kappa}B, but not Induced NF-{kappa}B, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells. Mol Cancer Res 4: 715-728 [Abstract] [Full Text]  
  • Croxton, R., Puto, L. A., de Belle, I., Thomas, M., Torii, S., Hanaii, F., Cuddy, M., Reed, J. C. (2006). Daxx Represses Expression of a Subset of Antiapoptotic Genes Regulated by Nuclear Factor-{kappa}B.. Cancer Res. 66: 9026-9035 [Abstract] [Full Text]  
  • Chen, Y., Budd, R. C., Kelm, R. J. Jr, Sobel, B. E., Schneider, D. J. (2006). Augmentation of Proliferation of Vascular Smooth Muscle Cells by Plasminogen Activator Inhibitor Type 1. Arterioscler. Thromb. Vasc. Bio. 26: 1777-1783 [Abstract] [Full Text]  
  • Zhang, H.-G., Liu, C., Su, K., Yu, S., Zhang, L., Zhang, S., Wang, J., Cao, X., Grizzle, W., Kimberly, R. P. (2006). A Membrane Form of TNF-{alpha} Presented by Exosomes Delays T Cell Activation-Induced Cell Death.. J. Immunol. 176: 7385-7393 [Abstract] [Full Text]  
  • Gao, S., Wang, H., Lee, P., Melamed, J., Li, C. X, Zhang, F., Wu, H., Zhou, L., Wang, Z. (2006). Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland.. J Mol Endocrinol 36: 463-483 [Abstract] [Full Text]  
  • Takahashi, H., Feuerhake, F., Kutok, J. L., Monti, S., Dal Cin, P., Neuberg, D., Aster, J. C., Shipp, M. A. (2006). FAS Death Domain Deletions and Cellular FADD-like Interleukin 1{beta} Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes.. Clin. Cancer Res. 12: 3265-3271 [Abstract] [Full Text]  
  • Krueger, A., Fas, S. C., Giaisi, M., Bleumink, M., Merling, A., Stumpf, C., Baumann, S., Holtkotte, D., Bosch, V., Krammer, P. H., Li-Weber, M. (2006). HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 107: 3933-3939 [Abstract] [Full Text]  
  • Saito, K., Meyer, K., Warner, R., Basu, A., Ray, R. B., Ray, R. (2006). Hepatitis C Virus Core Protein Inhibits Tumor Necrosis Factor Alpha-Mediated Apoptosis by a Protective Effect Involving Cellular FLICE Inhibitory Protein. J. Virol. 80: 4372-4379 [Abstract] [Full Text]  
  • Liu, S. F., Malik, A. B. (2006). NF-{kappa}B activation as a pathological mechanism of septic shock and inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L622-L645 [Abstract] [Full Text]  
  • Li, Y. C., Park, M. J., Ye, S.-K., Kim, C.-W., Kim, Y.-N. (2006). Elevated Levels of Cholesterol-Rich Lipid Rafts in Cancer Cells Are Correlated with Apoptosis Sensitivity Induced by Cholesterol-Depleting Agents. Am. J. Pathol. 168: 1107-1118 [Abstract] [Full Text]  
  • Cudrici, C., Niculescu, F., Jensen, T., Zafranskaia, E., Fosbrink, M., Rus, V., Shin, M. L., Rus, H. (2006). C5b-9 Terminal Complex Protects Oligodendrocytes from Apoptotic Cell Death by Inhibiting Caspase-8 Processing and Up-Regulating FLIP.. J. Immunol. 176: 3173-3180 [Abstract] [Full Text]  
  • Sangwan, V., Paliouras, G. N., Cheng, A., Dube, N., Tremblay, M. L., Park, M. (2006). Protein-tyrosine Phosphatase 1B Deficiency Protects against Fas-induced Hepatic Failure. J. Biol. Chem. 281: 221-228 [Abstract] [Full Text]  
  • Lemarie, A., Morzadec, C., Merino, D., Micheau, O., Fardel, O., Vernhet, L. (2006). Arsenic Trioxide Induces Apoptosis of Human Monocytes during Macrophagic Differentiation through Nuclear Factor-{kappa}B-Related Survival Pathway Down-Regulation. J. Pharmacol. Exp. Ther. 316: 304-314 [Abstract] [Full Text]  
  • Piazzolla, D., Meissl, K., Kucerova, L., Rubiolo, C., Baccarini, M. (2005). Raf-1 sets the threshold of Fas sensitivity by modulating Rok-{alpha} signaling. JCB 171: 1013-1022 [Abstract] [Full Text]  
  • Kim, K. M., Song, J. J., An, J. Y., Kwon, Y. T., Lee, Y. J. (2005). Pretreatment of Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene Expression. J. Biol. Chem. 280: 41047-41056 [Abstract] [Full Text]  
  • Zhang, S., Shen, H.-M., Ong, C. N. (2005). Down-regulation of c-FLIP contributes to the sensitization effect of 3,3'-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Molecular Cancer Therapeutics 4: 1972-1981 [Abstract] [Full Text]  
  • Kerbauy, D. M. B., Lesnikov, V., Abbasi, N., Seal, S., Scott, B., Deeg, H. J. (2005). NF-{kappa}B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 106: 3917-3925 [Abstract] [Full Text]  
  • Shi, R.-X., Ong, C.-N., Shen, H.-M. (2005). Protein Kinase C Inhibition and X-Linked Inhibitor of Apoptosis Protein Degradation Contribute to the Sensitization Effect of Luteolin on Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Cancer Cells. Cancer Res. 65: 7815-7823 [Abstract] [Full Text]  
  • Feuerhake, F., Kutok, J. L., Monti, S., Chen, W., LaCasce, A. S., Cattoretti, G., Kurtin, P., Pinkus, G. S., de Leval, L., Harris, N. L., Savage, K. J., Neuberg, D., Habermann, T. M., Dalla-Favera, R., Golub, T. R., Aster, J. C., Shipp, M. A. (2005). NF{kappa}B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106: 1392-1399 [Abstract] [Full Text]  
  • Poukkula, M., Kaunisto, A., Hietakangas, V., Denessiouk, K., Katajamaki, T., Johnson, M. S., Sistonen, L., Eriksson, J. E. (2005). Rapid Turnover of c-FLIPshort Is Determined by Its Unique C-terminal Tail. J. Biol. Chem. 280: 27345-27355 [Abstract] [Full Text]  
  • Lesne, S., Gabriel, C., Nelson, D. A., White, E., MacKenzie, E. T., Vivien, D., Buisson, A. (2005). Akt-dependent Expression of NAIP-1 Protects Neurons against Amyloid-{beta} Toxicity. J. Biol. Chem. 280: 24941-24947 [Abstract] [Full Text]  
  • Powell, D. J. Jr, Dudley, M. E., Robbins, P. F., Rosenberg, S. A. (2005). Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241-250 [Abstract] [Full Text]  
  • Wachter, T., Sprick, M., Hausmann, D., Kerstan, A., McPherson, K., Stassi, G., Brocker, E.-B., Walczak, H., Leverkus, M. (2004). cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF-{kappa}B Activation at the Death-inducing Signaling Complex in Human Keratinocytes. J. Biol. Chem. 279: 52824-52834 [Abstract] [Full Text]  
  • Li, W., Simarro, M., Kedersha, N., Anderson, P. (2004). FAST Is a Survival Protein That Senses Mitochondrial Stress and Modulates TIA-1-Regulated Changes in Protein Expression. Mol. Cell. Biol. 24: 10718-10732 [Abstract] [Full Text]  
  • Gricks, C. S., Zahrieh, D., Zauls, A. J., Gorgun, G., Drandi, D., Mauerer, K., Neuberg, D., Gribben, J. G. (2004). Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 104: 4002-4009 [Abstract] [Full Text]  
  • Basso, K., Klein, U., Niu, H., Stolovitzky, G. A., Tu, Y., Califano, A., Cattoretti, G., Dalla-Favera, R. (2004). Tracking CD40 signaling during germinal center development. Blood 104: 4088-4096 [Abstract] [Full Text]  
  • Li, Q., Ching, A. K.-K., Chan, B. C.-L., Chow, S. K.-Y., Lim, P.-L., Ho, T. C.-Y., Ip, W.-K., Wong, C.-K., Lam, C. W.-K., Lee, K. K.-H., Chan, J. Y.-H., Chui, Y.-L. (2004). A Death Receptor-associated Anti-apoptotic Protein, BRE, Inhibits Mitochondrial Apoptotic Pathway. J. Biol. Chem. 279: 52106-52116 [Abstract] [Full Text]  
  • Tseveleki, V., Bauer, J., Taoufik, E., Ruan, C., Leondiadis, L., Haralambous, S., Lassmann, H., Probert, L. (2004). Cellular FLIP (Long Isoform) Overexpression in T Cells Drives Th2 Effector Responses and Promotes Immunoregulation in Experimental Autoimmune Encephalomyelitis. J. Immunol. 173: 6619-6626 [Abstract] [Full Text]  
  • Wang, W., Cassidy, J., O'Brien, V., Ryan, K. M., Collie-Duguid, E. (2004). Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells. Cancer Res. 64: 8167-8176 [Abstract] [Full Text]  
  • Zhang, X., Jin, T.-G., Yang, H., DeWolf, W. C., Khosravi-Far, R., Olumi, A. F. (2004). Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer. Cancer Res. 64: 7086-7091 [Abstract] [Full Text]  
  • Tucker, S. J., Rae, C., Littlejohn, A. F., Paul, A., MacEwan, D. J. (2004). Switching leukemia cell phenotype between life and death. Proc. Natl. Acad. Sci. USA 101: 12940-12945 [Abstract] [Full Text]  
  • Amiri, K. I., Horton, L. W., LaFleur, B. J., Sosman, J. A., Richmond, A. (2004). Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition: Implication for Bortezomib (VELCADE, PS-341) as a Therapeutic Agent for Malignant Melanoma. Cancer Res. 64: 4912-4918 [Abstract] [Full Text]  
  • Yang, P., McKay, B. S., Allen, J. B., Jaffe, G. J. (2004). Effect of NF-{kappa}B Inhibition on TNF-{alpha}-Induced Apoptosis in Human RPE Cells. IOVS 45: 2438-2446 [Abstract] [Full Text]  
  • Lamkanfi, M., Kalai, M., Saelens, X., Declercq, W., Vandenabeele, P. (2004). Caspase-1 Activates Nuclear Factor of the {kappa}-Enhancer in B Cells Independently of Its Enzymatic Activity. J. Biol. Chem. 279: 24785-24793 [Abstract] [Full Text]  
  • Suhara, T., Fukuo, K., Yasuda, O., Tsubakimoto, M., Takemura, Y., Kawamoto, H., Yokoi, T., Mogi, M., Kaimoto, T., Ogihara, T. (2004). Homocysteine Enhances Endothelial Apoptosis via Upregulation of Fas-Mediated Pathways. Hypertension 43: 1208-1213 [Abstract] [Full Text]  
  • Ivanov, V. N., Hei, T. K. (2004). Arsenite Sensitizes Human Melanomas to Apoptosis via Tumor Necrosis Factor {alpha}-mediated Pathway. J. Biol. Chem. 279: 22747-22758 [Abstract] [Full Text]  
  • Chau, B. N., Chen, T.-T., Wan, Y. Y., DeGregori, J., Wang, J. Y. J. (2004). Tumor Necrosis Factor Alpha-Induced Apoptosis Requires p73 and c-ABL Activation Downstream of RB Degradation. Mol. Cell. Biol. 24: 4438-4447 [Abstract] [Full Text]  
  • Dutton, A., O'Neil, J. D., Milner, A. E., Reynolds, G. M., Starczynski, J., Crocker, J., Young, L. S., Murray, P. G. (2004). Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc. Natl. Acad. Sci. USA 101: 6611-6616 [Abstract] [Full Text]  
  • Zhang, J., Xu, L.-G., Han, K.-J., Shu, H.-B. (2004). Identification of a ZU5 and Death Domain-containing Inhibitor of NF-{kappa}B. J. Biol. Chem. 279: 17819-17825 [Abstract] [Full Text]  
  • Cahir-McFarland, E. D., Carter, K., Rosenwald, A., Giltnane, J. M., Henrickson, S. E., Staudt, L. M., Kieff, E. (2004). Role of NF-{kappa}B in Cell Survival and Transcription of Latent Membrane Protein 1-Expressing or Epstein-Barr Virus Latency III-Infected Cells. J. Virol. 78: 4108-4119 [Abstract] [Full Text]  
  • Benoit, V., Chariot, A., Delacroix, L., Deregowski, V., Jacobs, N., Merville, M.-P., Bours, V. (2004). Caspase-8-Dependent HER-2 Cleavage in Response to Tumor Necrosis Factor {alpha} Stimulation Is Counteracted by Nuclear Factor {kappa}B through c-FLIP-L Expression. Cancer Res. 64: 2684-2691 [Abstract] [Full Text]  
  • Shisler, J. L., Jin, X.-L. (2004). The Vaccinia Virus K1L Gene Product Inhibits Host NF-{kappa}B Activation by Preventing I{kappa}B{alpha} Degradation. J. Virol. 78: 3553-3560 [Abstract] [Full Text]  
  • Takada, Y., Aggarwal, B. B. (2004). Flavopiridol Inhibits NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of I{kappa}B{alpha} Kinase and p65 Phosphorylation: ABROGATION OF CYCLIN D1, CYCLOOXYGENASE-2, AND MATRIX METALLOPROTEASE-9. J. Biol. Chem. 279: 4750-4759 [Abstract] [Full Text]  
  • Kaiser, W. J., Kaufman, J. L., Offermann, M. K. (2004). IFN-{alpha} Sensitizes Human Umbilical Vein Endothelial Cells to Apoptosis Induced by Double-Stranded RNA. J. Immunol. 172: 1699-1710 [Abstract] [Full Text]  
  • Mistry, P., Deacon, K., Mistry, S., Blank, J., Patel, R. (2004). NF-{kappa}B Promotes Survival during Mitotic Cell Cycle Arrest. J. Biol. Chem. 279: 1482-1490 [Abstract] [Full Text]  
  • Waxman, D. J., Schwartz, P. S. (2003). Harnessing Apoptosis for Improved Anticancer Gene Therapy. Cancer Res. 63: 8563-8572 [Abstract] [Full Text]  
  • Hendriks, J., Xiao, Y., Borst, J. (2003). CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell Pool. JEM 198: 1369-1380 [Abstract] [Full Text]  
  • Zazzeroni, F., Papa, S., Algeciras-Schimnich, A., Alvarez, K., Melis, T., Bubici, C., Majewski, N., Hay, N., De Smaele, E., Peter, M. E., Franzoso, G. (2003). Gadd45{beta} mediates the protective effects of CD40 costimulation against Fas-induced apoptosis. Blood 102: 3270-3279 [Abstract] [Full Text]  
  • Bezzi, M., Hasmim, M., Bieler, G., Dormond, O., Ruegg, C. (2003). Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death: EVIDENCE FOR THE SUPPRESSION OF SUSTAINED ACTIVATION OF FOCAL ADHESION KINASE AND PROTEIN KINASE B/Akt. J. Biol. Chem. 278: 43603-43614 [Abstract] [Full Text]  
  • Sun, Y., Mochizuki, Y., Majerus, P. W. (2003). Inositol 1,3,4-Trisphosphate 5/6-Kinase Inhibits Tumor Necrosis Factor-induced Apoptosis. J. Biol. Chem. 278: 43645-43653 [Abstract] [Full Text]  
  • Prendes, M., Zheng, Y., Beg, A. A. (2003). Regulation of Developing B Cell Survival by RelA-Containing NF-{kappa}B Complexes. J. Immunol. 171: 3963-3969 [Abstract] [Full Text]  
  • Wu, Y., Han, B., Luo, H., Roduit, R., Salcedo, T. W., Moore, P. A., Zhang, J., Wu, J. (2003). DcR3/TR6 Effectively Prevents Islet Primary Nonfunction After Transplantation. Diabetes 52: 2279-2286 [Abstract] [Full Text]  
  • Kuenzi, P., Schneider, P., Dobbelaere, D. A. E. (2003). Theileria parva-Transformed T Cells Show Enhanced Resistance to Fas/Fas Ligand-Induced Apoptosis. J. Immunol. 171: 1224-1231 [Abstract] [Full Text]  
  • Zhang, B., Hirahashi, J., Cullere, X., Mayadas, T. N. (2003). Elucidation of Molecular Events Leading to Neutrophil Apoptosis following Phagocytosis: CROSS-TALK BETWEEN CASPASE 8, REACTIVE OXYGEN SPECIES, AND MAPK/ERK ACTIVATION. J. Biol. Chem. 278: 28443-28454 [Abstract] [Full Text]  
  • Wu, M., Xu, L.-G., Zhai, Z., Shu, H.-B. (2003). SINK Is a p65-interacting Negative Regulator of NF-{kappa}B-dependent Transcription. J. Biol. Chem. 278: 27072-27079 [Abstract] [Full Text]  
  • Suzuki, S., Suzuki, N., Mirtsos, C., Horacek, T., Lye, E., Noh, S.-K., Ho, A., Bouchard, D., Mak, T. W., Yeh, W.-C. (2003). Nur77 as a survival factor in tumor necrosis factor signaling. Proc. Natl. Acad. Sci. USA 100: 8276-8280 [Abstract] [Full Text]  
  • Madge, L. A., Li, J.-H., Choi, J., Pober, J. S. (2003). Inhibition of Phosphatidylinositol 3-Kinase Sensitizes Vascular Endothelial Cells to Cytokine-initiated Cathepsin-dependent Apoptosis. J. Biol. Chem. 278: 21295-21306 [Abstract] [Full Text]  
  • Wajant, H. (2003). Targeting the FLICE Inhibitory Protein (FLIP) in Cancer Therapy. Mol. Interv. 3: 124-127 [Abstract] [Full Text]  
  • Osawa, Y., Nagaki, M., Banno, Y., Brenner, D. A., Nozawa, Y., Moriwaki, H., Nakashima, S. (2003). Expression of the NF-{kappa}B Target Gene X-Ray-Inducible Immediate Early Response Factor-1 Short Enhances TNF-{alpha}-Induced Hepatocyte Apoptosis by Inhibiting Akt Activation. J. Immunol. 170: 4053-4060 [Abstract] [Full Text]  
  • Wu, W.-S., Xu, Z.-X., Hittelman, W. N., Salomoni, P., Pandolfi, P. P., Chang, K.-S. (2003). Promyelocytic Leukemia Protein Sensitizes Tumor Necrosis Factor alpha -Induced Apoptosis by Inhibiting the NF-kappa B Survival Pathway. J. Biol. Chem. 278: 12294-12304 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Micheau, O.
Right arrow Articles by Tschopp, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Micheau, O.
Right arrow Articles by Tschopp, J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»